Skip to main content
Figure 2 | Alzheimer's Research & Therapy

Figure 2

From: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Figure 2

Summary of efficacy data at weeks 12 and 24. Mean change from baseline to week 24 in (a) Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-Cog), (b) Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) and (c) Mini-Mental State Examination (MMSE), according to observed cases dataset analysis on the intent-to-treat population. N, number of evaluable patients at each time point (masitinib-treated versus placebo, respectively).

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193